Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | FGFR2 C382R FGFR2 M538I FGFR2 N550D FGFR2 V565I |
Therapy | Tinengotinib |
Indication/Tumor Type | intrahepatic cholangiocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR2 C382R FGFR2 M538I FGFR2 N550D FGFR2 V565I | intrahepatic cholangiocarcinoma | predicted - sensitive | Tinengotinib | Case Reports/Case Series | Actionable | In a clinical case study, Tinengotinib (TT-00420) treatment resulted in 37% tumor shrinkage in a patient with intrahepatic cholangiocarcinoma harboring FGFR2 C382R, N550D, V565I, and M538I (PMID: 39706336). | 39706336 |
PubMed Id | Reference Title | Details |
---|---|---|
(39706336) | A Model for Decoding Resistance in Precision Oncology: Acquired Resistance to FGFR inhibitors in Cholangiocarcinoma. | Full reference... |